RxDoctor Payments Data

Terri Brown

Adult Health · Detroit, MINPI 1376761106

Payments from drug & device makers

$1,930in general payments, 2019–2025

Across 19 payments — averaging $101.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$683
  • Lilly USA, LLC$259
  • Abbott$171
  • AstraZeneca$127
  • Sanofi$126
  • Biohaven Pharmaceuticals, Inc.$123
  • plus $441 from 5 others

What the payments were for

  • Food & beverage$1,90098%
  • Education$312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,930 in reported general payments places this provider in the 80th percentile of 527 adult health providers in Michigan.

See all adult health providers in Michigan

Medicare billing

Part B allowed, 2024
$12,718
Medicare patients
77
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide213$400,849
TrulicityDulaglutide69$122,431
MounjaroTirzepatide54$69,794
JardianceEmpagliflozin41$58,148
Lantus SolostarInsulin Glargine,hum.Rec.Anlog234$34,382
Novolog FlexpenInsulin Aspart121$30,353
Humulin R U-500 KwikpenInsulin Regular, Human28$30,264
Tresiba Flextouch U-100Insulin Degludec45$29,774
Humulin R U-500Insulin Regular, Human18$28,221
Tresiba Flextouch U-200Insulin Degludec12$21,757
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$17,559
JanuviaSitagliptin Phosphate11$12,805
Humalog Kwikpen U-100Insulin Lispro40$10,261
BaqsimiGlucagon17$10,157
Ultra-Fine Short Pen NeedlePen Needle, Diabetic83$10,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$683$400,849213 claims
Lilly USA, LLCTrulicity, Mounjaro, Baqsimi$259$202,383140 claims
Boehringer IngelheimJardiance$19$58,14841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 527 adult health providers in Michigan.

Other adult health in Detroit

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →